Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Select Medical Holdings (SEM) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Select Medical Holdings (SEM) over the last 17 years, with Q3 2025 value amounting to $122.2 million.

  • Select Medical Holdings' Free Cash Flow fell 620.25% to $122.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.0 million, marking a year-over-year decrease of 5063.58%. This contributed to the annual value of $295.7 million for FY2024, which is 1620.23% down from last year.
  • As of Q3 2025, Select Medical Holdings' Free Cash Flow stood at $122.2 million, which was down 620.25% from $45.6 million recorded in Q2 2025.
  • Over the past 5 years, Select Medical Holdings' Free Cash Flow peaked at $222.6 million during Q2 2024, and registered a low of -$119.2 million during Q1 2024.
  • Its 5-year average for Free Cash Flow is $56.6 million, with a median of $62.0 million in 2024.
  • As far as peak fluctuations go, Select Medical Holdings' Free Cash Flow skyrocketed by 400518.87% in 2021, and later plummeted by 150115.51% in 2024.
  • Select Medical Holdings' Free Cash Flow (Quarter) stood at -$115.9 million in 2021, then soared by 63.15% to -$42.7 million in 2022, then skyrocketed by 378.25% to $118.8 million in 2023, then tumbled by 47.83% to $62.0 million in 2024, then soared by 97.1% to $122.2 million in 2025.
  • Its last three reported values are $122.2 million in Q3 2025, $45.6 million for Q2 2025, and -$55.8 million during Q1 2025.